If you’re looking for a practical breakdown of ICD-10 coding and classification in leukemia management, here’s the short version: leukemia codes live in the C91–C95 range, organized by cell lineage (lymphoid vs. myeloid) and disease tempo (acute vs. chronic). Getting these codes right isn’t just bureaucratic — it directly affects reimbursement, clinical trial eligibility, treatment authorization, and cancer registry accuracy.
But the coding gets granular fast. A patient with acute myeloid leukemia who achieves remission doesn’t keep the same code as one with active disease. A chronic lymphocytic leukemia patient on ibrutinib needs different documentation than one under watchful waiting. Below, I’ll walk through every major leukemia ICD-10 code, the most common coding mistakes I see in practice, and how proper classification actually shapes patient care.
ICD-10 Leukemia Codes at a Glance: C91–C95
The ICD-10-CM system classifies leukemia into five primary code families. Each family covers a specific cell lineage or pattern, with further digits specifying whether the disease is in remission, relapse, or neither.
| ICD-10 Code | Leukemia Type | Key Notes |
|---|---|---|
| C91.0_ | Acute lymphoblastic leukemia (ALL) | Most common childhood leukemia (~80% of pediatric cases) |
| C91.1_ | Chronic lymphocytic leukemia (CLL) | Most common adult leukemia in Western countries |
| C91.4_ | Hairy cell leukemia | Rare B-cell neoplasm; BRAF V600E mutation in ~100% of cases |
| C92.0_ | Acute myeloid leukemia (AML) | ≥20% blasts in marrow per WHO criteria; median age at diagnosis ~68 |
| C92.1_ | Chronic myeloid leukemia (CML) | Defined by BCR-ABL1 fusion; ~95% Philadelphia chromosome positive |
| C92.4_ | Acute promyelocytic leukemia (APL) | PML-RARA fusion; medical emergency requiring immediate ATRA |
| C93.0_ | Acute monoblastic/monocytic leukemia | AML subtype with monocytic differentiation |
| C94.0_ | Acute erythroid leukemia | Rare; reclassified under MDS in some WHO 2022 schemas |
| C95.0_ | Acute leukemia of unspecified cell type | Use only when lineage truly cannot be determined |
The final digit in each code specifies disease status: 0 = not having achieved remission, 1 = in remission, 2 = in relapse. For example, C92.01 means “AML, in remission.” This single digit matters enormously for treatment authorization and outcomes tracking.
Why Accurate Leukemia Coding Actually Matters Clinically
I’ve seen prior authorizations denied because a coder documented C95.0 (unspecified acute leukemia) when the pathology clearly showed AML with FLT3-ITD mutation. That level of imprecision can delay midostaurin approval by days — days a patient with newly diagnosed AML doesn’t have.
Accurate ICD-10 coding and classification in leukemia management serves several concrete purposes:
- Insurance preauthorization: Targeted therapies like venetoclax (CLL), gilteritinib (FLT3+ AML), and imatinib (CML) each require subtype-specific codes.
- Cancer registry data: The Surveillance, Epidemiology, and End Results (SEER) program relies on ICD-10 to track the ~60,000+ new leukemia cases diagnosed annually in the U.S.
- Clinical trial matching: Eligibility criteria reference specific ICD-10 codes. An imprecise code can make a patient invisible to trial screening algorithms.
- Quality metrics: Hospital quality measures and mortality benchmarks are stratified by leukemia subtype.
Common ICD-10 Coding Errors in Leukemia
1. Using “Unspecified” Codes When Data Exists
C95.0 and C95.9 (unspecified leukemia) should be last-resort codes. If flow cytometry, cytogenetics, or molecular testing has been performed — and in 2024, it almost always has — the code should reflect the specific subtype. Over-reliance on unspecified codes is one of the most common audit triggers.
2. Not Updating Remission Status
A patient who achieves complete remission after induction chemotherapy should transition from C92.00 to C92.01. Failing to update this creates a medical record that looks like the patient has perpetually active disease, which distorts survival data and can confuse cross-covering physicians.
3. Confusing MDS with AML
Myelodysplastic syndromes (MDS) are coded under D46, not C92. However, when MDS transforms to AML (blast count ≥20%), the code shifts to C92.0_ with a secondary code capturing the MDS history. Missing this transition under-reports AML incidence and can affect treatment coverage.
4. Ignoring Laterality and Specificity in Related Codes
Leukemia often coexists with coded complications — splenomegaly (R16.1), tumor lysis syndrome (E88.3), or febrile neutropenia (D70.1). Omitting these secondary codes understates disease severity and resource utilization.
How ICD-10 Codes Map to Leukemia Subtypes by Genetics
Modern leukemia classification leans heavily on molecular genetics, not just morphology. The WHO 2022 classification and the newer ICC (International Consensus Classification) define many leukemia entities by their genetic drivers. Here’s how key molecular findings map to ICD-10:
| Molecular Feature | Leukemia Subtype | ICD-10 Code |
|---|---|---|
| BCR-ABL1 (Philadelphia chromosome) | CML / Ph+ ALL | C92.1_ / C91.0_ |
| PML-RARA | Acute promyelocytic leukemia | C92.4_ |
| FLT3-ITD or FLT3-TKD | AML with FLT3 mutation | C92.0_ (no separate FLT3-specific code) |
| NPM1 mutation | AML with mutated NPM1 | C92.0_ |
| CSF3R mutation | Chronic neutrophilic leukemia | C93.1_ |
| del(17p) / TP53 mutation | CLL (high-risk) | C91.1_ |
Notice that ICD-10 doesn’t always have unique codes for molecularly defined subtypes. FLT3-mutated AML and NPM1-mutated AML share the same C92.0_ code, even though their prognosis and treatment differ dramatically. This is a known limitation, and ICD-11 — already adopted by the WHO but not yet implemented in U.S. billing — is expected to offer more molecular granularity.
ICD-10 Coding Tips for Specific Clinical Scenarios
- Newly diagnosed AML, starting induction: Code C92.00. Add Z85.6 only if there is a prior personal history of leukemia (i.e., relapse after a period of remission).
- CML patient stable on imatinib: Code C92.10 (CML, not having achieved remission) unless a documented molecular remission (BCR-ABL1 ≤0.1% on IS) qualifies for C92.11.
- CLL on watch-and-wait: Still coded as C91.10. There is no “inactive” or “indolent” modifier in ICD-10. The disease exists or it doesn’t.
- Post-transplant AML patient in remission: C92.01, plus Z94.81 (bone marrow transplant status).
Frequently Asked Questions
What is the ICD-10 code for acute myeloid leukemia?
The base code is C92.0. You add a final digit for status: C92.00 (not in remission), C92.01 (in remission), or C92.02 (in relapse). Promyelocytic Leukemia: From Definition to…”>Acute promyelocytic leukemia — a specific AML subtype — has its own code: C92.4_.
Is there a separate ICD-10 code for FLT3-positive AML?
No. As of ICD-10-CM 2024, FLT3-mutated AML is still coded as C92.0_. There is no modifier for molecular subtype. You should document the mutation in the clinical record, but the billing code doesn’t distinguish it from other AML variants.
How do I code leukemia that has transformed from MDS?
Once the blast count hits ≥20% and AML criteria are met, you code C92.0_ for the AML. You can add D46.9 or the specific MDS code as a secondary diagnosis to capture the history, along with Z85.6 if applicable. The sequencing matters — list the active AML as the principal diagnosis.
What’s the difference between C91.1 and C83 for lymphocytic neoplasms?
C91.1 is specifically for chronic lymphocytic leukemia (a disease primarily in blood and marrow). C83 covers diffuse large B-cell lymphoma and other non-Hodgkin lymphomas that are primarily nodal. CLL and small lymphocytic lymphoma (SLL) are the same disease biologically, but CLL is coded under C91.1 while SLL is coded under C83.0_. The distinction depends on whether the dominant disease burden is in blood/marrow (CLL) or lymph nodes (SLL).
When will ICD-11 replace ICD-10 for leukemia coding in the U.S.?
No firm date has been set. The WHO officially released ICD-11 in 2019, but U.S. adoption requires CMS approval and massive infrastructure changes. Most experts estimate implementation is at least several years away. For now, ICD-10-CM remains the standard for all U.S. clinical and billing documentation.
Key Takeaways
- Leukemia ICD-10 codes span C91–C95, organized by lineage and acuity. The final digit captures remission status — don’t forget to update it.
- Avoid unspecified codes (C95._) whenever molecular and flow cytometry data are available.
- ICD-10 doesn’t capture molecular subtypes like FLT3 or NPM1 mutations — document these in the clinical narrative for treatment justification.
- Proper ICD-10 coding and classification in leukemia management affects everything from drug approvals to clinical trial matching to national cancer statistics.
- If you’re a patient and your insurance denies a targeted therapy, ask your oncology team to verify that the ICD-10 code on the claim matches your specific leukemia subtype. A coding mismatch is one of the most fixable reasons for a denial.
